Cost-minimization analysis between intravenous iron sucrose and iron sucrose similar in hemodialysis patients.

Arnaud PagèsCéline PorteilsIsabelle LabadensMatthieu ParmierSamantha OsesDamien SemelyMarion BourdoncleBruno SeigneuricArnaud Del BelloBlandine Juillard-Condat

Published in: Expert review of pharmacoeconomics & outcomes research (2019)

This cost minimization analysis suggests that for chronic hemodialysis patients, iron sucrose and iron sucrose similar have the same efficacy and that using iron sucrose similar was more expensive in 66.7% of iterations.

Keyphrases

iron deficiency
high dose
low dose
data analysis